Market Assessment, Asthma Unmet Need US/EU 2016 Report

Although several effective anti-inflammatory agents and bronchodilators are currently available for controlling disease in mild asthmatics, unmet needs exist in treating moderate to severe disease. According to the insights of surveyed U.S. and European pulmonologists, greater reduction in exacerbation rate and greater improvement in quality of life are key areas of unmet need for moderate to severe asthma. Furthermore, novel agents with strong efficacy in reducing the rate of exacerbations will have considerable influence on physician prescribing decisions as competition among pharmacological agents rapidly increases in the moderate to severe asthma market.

Back to all Market Assessment reports

Contact us

Investors

Careers

Login

Asthma | Unmet Need | US/EU | 2016

Related Market Assessment Reports

Non-Small-Cell Lung Cancer – Current Treatment – Detailed, Expanded Analysis (US)

Breast Cancer – Unmet Need – Detailed, Expanded Analysis: Advanced Or Metastatic HER2-Positive Breast Cancer (US/EU)

Heart Failure – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Heart Failure – Reduced Ejection Fraction (US)

Heart Failure – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Heart Failure – Preserved Ejection Fraction (US)

Male Hypogonadism – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Male Hypogonadism (Low Testosterone) (US)